TY - JOUR
T1 - Primary and secondary hemostasis in patients with subclinical hypothyroidism
T2 - Effect of levothyroxine treatment
AU - Lupoli, Roberta
AU - Di Minno, Matteo Nicola Dario
AU - Tortora, Anna
AU - Scaravilli, Alessandra
AU - Cacciapuoti, Marianna
AU - Barba, Livia
AU - Di Minno, Alessandro
AU - Ambrosino, Pasquale
AU - Lupoli, Gelsy Arianna
AU - Lupoli, Giovanni
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Context: Subclinical hypothyroidism (SH) is associated with some abnormalities in primary and secondary hemostasis. Objective: The objective of the study was to evaluate changes in primary and secondary hemostasis induced by levothyroxine (L-T4) treatment in SH patients. Design: This was a prospective cohort study with a 6-month follow-up. Study Setting: Outpatients were referred to "Federico II" University of Naples. Patients: Subjects with a SH without previous/ongoing L-T4 therapy participated in the study. Main Outcome Measure: Changes in major hemostatic/fibrinolytic variables and platelet reactivity [mean platelet volume (MPV), arachidonic acid (AA), or ADP concentrations inducing a ≥ 50% irreversible aggregation (AC-50%)] in SH patients before and after a 6-month L-T4 treatment. Results: At baseline, 41 SH patients showed higher levels of factor VII activity (123.9±20.4 vs 107.7±12.2, P
AB - Context: Subclinical hypothyroidism (SH) is associated with some abnormalities in primary and secondary hemostasis. Objective: The objective of the study was to evaluate changes in primary and secondary hemostasis induced by levothyroxine (L-T4) treatment in SH patients. Design: This was a prospective cohort study with a 6-month follow-up. Study Setting: Outpatients were referred to "Federico II" University of Naples. Patients: Subjects with a SH without previous/ongoing L-T4 therapy participated in the study. Main Outcome Measure: Changes in major hemostatic/fibrinolytic variables and platelet reactivity [mean platelet volume (MPV), arachidonic acid (AA), or ADP concentrations inducing a ≥ 50% irreversible aggregation (AC-50%)] in SH patients before and after a 6-month L-T4 treatment. Results: At baseline, 41 SH patients showed higher levels of factor VII activity (123.9±20.4 vs 107.7±12.2, P
UR - http://www.scopus.com/inward/record.url?scp=84942302233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942302233&partnerID=8YFLogxK
U2 - 10.1210/jc.2015-1726
DO - 10.1210/jc.2015-1726
M3 - Article
C2 - 25955227
AN - SCOPUS:84942302233
VL - 100
SP - 2659
EP - 2665
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 7
ER -